FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen
1 finding from 1 review
Choice of an option aligned with each woman’s values and preferences · women aged 38 to 71 years at average to moderate risk of breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Choice of an option aligned with each woman’s values and preferences · women aged 40 to 75 years at average to moderate risk of breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete healing of surgical wound · people with stage IV pressure ulcers
1 finding from 1 review
Wound dehiscence · people with stage IV pressure ulcers
1 finding from 1 review
Symptomatic DVT · passengers on a long haul flight (more than 4 hours)
1 finding from 1 review
Symptomless DVT · passengers on a long haul flight (more than 4 hours)
Compression stockings leads to lower symptomless DVT compared with no compression stockings (high certainty).
1 finding from 1 review
Pulmonary embolism · passengers on a long haul flight (more than 4 hours)
1 finding from 1 review
Death · passengers on a long haul flight (more than 4 hours)
1 finding from 1 review
Superficial vein thrombosis · passengers on a long haul flight (more than 4 hours)
Compression stockings showed no clear difference in superficial vein thrombosis compared with no compression stockings (moderate certainty).
1 finding from 1 review
Oedema · passengers on a long haul flight (more than 4 hours)
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment showed no clear difference in death at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher complete remission at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment may leads to higher recurrence of disease (relapse) at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to lower 100% increase in serum creatinine at final compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher adverse events: temporary/permanent discontinuation or… compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse events: infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether immunosuppressive treatment changes adverse events: infection at 3 years compared with placebo/no treatment/non‐immunosuppressive supportive treatment (very low certainty).
1 finding from 1 review